Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine.
Oregon Social Learning Center.
J Consult Clin Psychol. 2023 Apr;91(4):189-191. doi: 10.1037/ccp0000797. Epub 2023 Feb 13.
This article discusses psychosocial interventions in the contexts they are meant to be delivered. Prevention and intervention science often follow the linear pathway of preclinical or pre-intervention research-efficacy trials, effectiveness trials, and implementation studies-with the assessment of translation into public and population health impact occurring at the end. This linear translational pathway follows stages developed for ascertaining safe, efficacious, and effective dosages for biological compounds. This approach has created limitations in the need to rapidly deploy complex, multi-component, multilevel approaches to change behavior and improve health into widespread practice for diverse clinical and public health settings. While it is important to use efficacy trials when safety is yet to be established, when the risks are identified to be low, as is often the case for psychosocial interventions, we can go faster to achieve equitable population health impact. The authors recommend that clinical trialists engaged in intervention development incorporate two considerations in the next generation of prevention and intervention research. First, consider moving right to effectiveness or pragmatic trials, as the most valid test of an intervention is the est of that intervention in the context(s) in which it is intended. Second, when designing effectiveness studies, consider investigating questions related to both effectiveness (i.e., does the intervention improve clinical outcomes) and implementation (i.e., what supports are needed to deploy the intervention routinely in that context) to accelerate impact. As a matter of both ethics and equity, there is a need to expedite the research-to-practice pipeline at a pace faster than is made available through current approaches. (PsycInfo Database Record (c) 2023 APA, all rights reserved).
本文讨论了在预期环境下实施的心理社会干预措施。预防和干预科学通常遵循临床前或干预前研究-疗效试验、效果试验和实施研究的线性途径,而将其转化为公共和人群健康影响的评估则发生在最后。这种线性转化途径遵循了为确定生物化合物的安全、有效和有效剂量而开发的阶段。这种方法在需要快速部署复杂、多成分、多层次的方法来改变行为和改善健康以广泛应用于各种临床和公共卫生环境方面存在局限性。虽然在安全性尚未确立的情况下使用疗效试验很重要,但当风险被确定为低时,就像心理社会干预措施通常情况那样,我们可以更快地实现公平的人群健康影响。作者建议从事干预措施开发的临床试验人员在下一代预防和干预研究中考虑两个因素。首先,考虑直接进行效果或实用试验,因为对干预措施的最有效测试是在预期的环境中对该干预措施的评估。其次,在设计效果研究时,考虑调查与效果(即干预是否改善临床结果)和实施(即需要哪些支持才能在该环境中常规部署干预措施)相关的问题,以加速影响。出于伦理和公平的考虑,需要以比当前方法提供的更快的速度加快研究到实践的转化。